Drugs & Targets Keytruda receives FDA approvals in Hodgkin lymphoma indications October 16, 2020Vol.46 No.39
Drugs & Targets MD Anderson and Allogene Therapeutics collaborate to advance allogeneic CAR T therapy October 16, 2020Vol.46 No.39
Clinical Roundup Genomic study of 6,000 NCI-MATCH cancer patients leads to new clinical trial benchmarks October 16, 2020Vol.46 No.39
Clinical Roundup Miami Cancer Institute analysis shows developments for brain metastases patients October 16, 2020Vol.46 No.39
Clinical Roundup Napo Pharmaceuticals initiates phase III trial of Mytesi for prophylaxis of diarrhea in adult cancer patients October 16, 2020Vol.46 No.39
Clinical Roundup Phase II EV-201 study demonstrates 52% ORR in urothelial cancer October 16, 2020Vol.46 No.39
Clinical Roundup Virus-mimicking drug helps immune system target cunning cancer cells October 16, 2020Vol.46 No.39
COVID-19 & CancerTrials & Tribulations COVID and lung cancer: How experts in cancer and virology joined forces in a challenging time October 16, 2020Vol.46 No.39By Fred R. Hirsch
In Brief OSUCCC – James receives $7 million Program Project NCI grant renewal October 16, 2020Vol.46 No.39
